Skip to content

John D. Mccorvy

40 papers in the library · 3,483 citations · publishing 2012-2026

Papers

Sort Most recent Most cited

Deconstruction of lysergic acid diethylamide.

Proceedings of the National Academy of Sciences September 8, 2026 Andrian G Basargin, Andras Domokosa, Joseph J. Hennessey et al.

Of the classic psychedelics, lysergic acid diethylamide (LSD) is perhaps the best-known, but its complex chemical architecture has limited synthetic investigations aimed at generating analogues with improved safety and efficacy profiles. Here, we systematically deconstruct the tetracyclic ergoline core of LSD to create 9 simplified ergoline analogues (i.e., ergologs) and evaluate them in...

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy- N -methyl- N -isopropyltryptamine and Related Analogs

ACS Chemical Neuroscience May 27, 2026 Grant C. Glatfelter, Serena S. Schalk, Donna Walther et al.

High Resolution Image Download MS PowerPoint Slide Tryptamine psychedelics induce psychoactive effects via agonist actions at serotonin 2A receptors (5-HT 2A ), but the compounds are generally nonselective. 4-Methoxy- N -methyl- N -isopropyltryptamine (4-MeO-MiPT) is a 5-HT 2A agonist which also blocks the 5-HT transporter (SERT) and has blunted visual and other psychedelic effects in humans....

DOI: 10.1021/acschemneuro.6c00083 (opens in new tab) Serotonin transporter Tryptamine Partial agonist Blockade +8

Serotonergic Polypharmacology of 2-Halogenated Tryptamines.

bioRxiv : the preprint server for biology April 21, 2026 Jeanine Yacoub, Elena Bray, Jude Bayyat et al. preprint

Serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) and 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin) show therapeutic promise for psychiatric and neurodegenerative disorders but may be limited by liabilities from serotonin (5-HT)-2A mediated psychoactive effects and potential cardiotoxicity via 5-HT2B activation. To address these limitations, we designed and synthesized...

Correction to "Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights".

ACS Chemical Neuroscience March 4, 2026 Nina Kastner, Núria Nadal‐gratacós, Selina Hemmer et al. correction

Correction 1: Table 1.The analyses were conducted using the correct data, and all results, interpretations, and conclusions in the paper remain fully accurate.The issue is limited to the presentation of values in the table.Correction 2: p 4733, second paragraph, 1 st sentence.Thigmotaxis was evaluated to assess potential anxiety-like effects induced by the compounds.When comparing the tested...

Transforming Amino Acids into Serotonin 5-HT 2A Receptor Ligands Using Photochemistry

Journal of the American Chemical Society December 16, 2025 J.O.S. Beckett, Ryan Buzdygon, Steven Nguyen et al. 1 citation

A light-induced cyclization via a radical spin-center shift process that results in the direct functionalization of the indole ring at the C4-position is developed into a practical method for the synthesis of medicinally active, ring-constrained tryptamine analogs. Amino acids were coupled to tryptamine and irradiated with UV light to produce a library of lactams bridging the C3- and...

Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights

ACS Chemical Neuroscience December 2, 2025 Nina Kastner, Núria Nadal‐gratacós, Selina Hemmer et al.

3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, shows promise in treating depression and post-traumatic stress disorder (PTSD), resulting in breakthrough status. However, concerns regarding MDMA's abuse potential and cytotoxicity have sparked interest in developing safer analogues with similar therapeutic benefits. This study investigated the pharmacological properties of...

DOI: 10.1021/acschemneuro.5c00782 (opens in new tab) MDMA Norepinephrine transporter Monoamine neurotransmitter Dopamine transporter +8

Discovery of Highly Selective 5-HT2A Agonists Using Structure-Guided Design

Journal of Medicinal Chemistry September 25, 2025 Tyler G. Fenske, J. M. T. Mckee, Natalie G. Cavalco et al.

With a resurgence in interest in psychedelics as rapid-acting and durable neuroplastic therapies, there is a critical need to develop more selective 5-HT 2A agonists to investigate the basic neurobiological mechanisms of psychedelics. Here, we show that selectivity for 5-HT 2A over the closely related 5-HT 2C receptor can be leveraged using structure-based design to target residue L123 2.53 in...

Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.

ACS Chemical Neuroscience September 13, 2025 Emma M. Bonniwell, Rana Alabdali, Joseph J. Hennessey et al. 3 citations

The serotonin 2C receptor (5-HT 2C ) is a G protein-coupled receptor implicated in multiple physiological and psychological processes and has been investigated as a therapeutic target for neuropsychiatric conditions such as obesity, drug abuse, and depression. With renewed interest in serotonergic psychedelics for treating depression, 5-HT 2C may contribute to psychedelic-induced therapeutic...

DOI: 10.1021/acschemneuro.5c00647 (opens in new tab) Full text (opens in new tab) Psychedelics Hallucinogens Entheogens Mind-altering drugs +18

The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation.

Nature Neuroscience September 1, 2025 Isak K Aarrestad, Lindsay P. Cameron, Ethan M Fenton et al.

Nonhallucinogenic psychoplastogens, such as tabernanthalog (TBG), are being developed as potentially safer, more scalable alternatives to psychedelics for promoting neuronal growth and treating various brain conditions. Currently, it is unclear whether 5-hydroxytryptamine 2A (5-HT2A) receptors and immediate early gene (IEG) activation have a role in the neuroplasticity-promoting effects of...

The ABCs of psychedelics: a preclinical roadmap for drug discovery.

TIPS - Trends in Pharmacological Sciences August 28, 2025 Alex C. Kwan, John R. Mantsch, John D. Mccorvy 7 citations

There is growing interest in developing psychedelic-inspired drugs for treating psychiatric disorders. However, identifying next-generation psychedelic analogs with ideal receptor selectivity and true therapeutic efficacy remains a major challenge. Recent progress has been driven by advances in determining agonist-induced biased signal transduction, high-content behavioral phenotyping via...

Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice

ACS Pharmacology & Translational Science August 22, 2025 Devin P. Effinger, Serena S. Schalk, Jillian L. King et al. 3 citations

High Resolution Image Download MS PowerPoint Slide Microdosing, the prolonged ingestion of psychedelics at subhallucinogenic doses, has gained popularity for its perceived cognitive and emotional benefits. Psychedelics have high affinity for 5-HT 2B receptors, a receptor known to cause human heart disease with strong chronic activation. We investigated the effects of microdosed psychedelics on...

Biased Signaling in Psychedelic Action.

The Annual Review of Pharmacology and Toxicology August 12, 2025 Daniel Wacker, John D. Mccorvy 4 citations

Psychedelics show tremendous promise for treating psychiatric disorders and other illnesses, including pain and migraine. Despite decades of research, there is uncertainty which signaling mechanisms are necessary for rapid-acting and durable therapeutic effects of psychedelics. Although activation of the serotonin 5-HT 2A receptor is critical for their psychopharmacological effects, the precise...

Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice.

ACS Chemical Neuroscience December 18, 2024 Grant C. Glatfelter, Allison A Clark, Natalie G. Cavalco et al. 14 citations

5-methoxy-N,N-dimethyltrytpamine (5-MeO-DMT) analogs are used as recreational drugs, but they are also being developed as potential medicines, warranting further investigation into their pharmacology. Here, we investigated the neuropharmacology of 5-MeO-DMT and several of its N-alkyl, N-allyl, and 2-methyl analogs, with three major aims: 1) to determine in vitro receptor profiles for the...

Bioisosteric analogs of MDMA: Improving the pharmacological profile?

Journal of Neurochemistry September 1, 2024 Ana Sofia Alberto-Silva, Selina Hemmer, Hailey A. Bock et al. 10 citations

3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is re-emerging in clinical settings as a candidate for the treatment of specific neuropsychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive drug, typically regarded as an empathogen or entactogen, which leads to transporter-mediated monoamine release. Despite its therapeutic...

DOI: 10.1111/jnc.16149 (opens in new tab) Full text (opens in new tab) Psychopharmacology Drug-development Mental-health MDMA-Research +1

Bioisosteric analogs of MDMA with improved pharmacological profile.

bioRxiv : the preprint server for biology April 11, 2024 Ana Sofia Alberto-Silva, Selina Hemmer, Hailey A. Bock et al. preprint

3,4-Methylenedioxymethamphetamine (MDMA, ' ecstasy' ) is re-emerging in clinical settings as a candidate for the treatment of specific psychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive drug, typically regarded as an empathogen or entactogen, which leads to transporter-mediated monoamine release. Despite its therapeutic...

DOI: 10.1101/2024.04.08.588083 (opens in new tab) Full text (opens in new tab) Psychedelics Drug development Mental health therapy MDMA Research

Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala.

Neuropsychopharmacology April 1, 2024 Thomas J. Kelly, Emma M. Bonniwell, Lianwei Mu et al. 26 citations

Psychedelics such as psilocybin show great promise for the treatment of depression and PTSD, but their long duration of action poses practical limitations for patient access. 4-OH-DiPT is a fast-acting and shorter-lasting derivative of psilocybin. Here we characterized the pharmacological profile of 4-OH-DiPT and examined its impact on fear extinction learning as well as a potential mechanism...

DOI: 10.1038/s41386-023-01744-8 (opens in new tab) Full text (opens in new tab) Psychopharmacology Anxiety-treatment Fear-response Brain-chemistry

Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential.

Nature Communications December 15, 2023 Jason Wallach, Andrew B. Cao, Maggie M. Calkins et al. 153 citations

Abstract Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT 2A receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT 2A -Gq/11 and β-arrestin2 transducers, making their respective roles unclear. To elucidate this, we develop a series of 5-HT 2A -selective ligands with varying Gq efficacies, including β-arrestin-biased...

DOI: 10.1038/s41467-023-44016-1 (opens in new tab) Full text (opens in new tab) Psychedelics Hallucinogens Psychoactive compounds Mind-altering substances +13

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.

Journal of Neuroscience November 8, 2023 Lindsay P. Cameron, Joseph Benetatos, Vern Lewis et al. 88 citations

Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects and unique mechanisms of action. These compounds exert their primary effects through activating serotonin 5-HT2A receptors, found predominantly in cortical regions. By interacting with these receptors, serotonergic psychedelics induce alterations in...

DOI: 10.1523/jneurosci.1384-23.2023 (opens in new tab) Full text (opens in new tab) Psychedelics Brain chemistry Mental health Pharmacology

Molecular insights into GPCR mechanisms for drugs of abuse.

Journal of Biological Chemistry September 1, 2023 Omar B Sanchez-Reyes, Gregory Zilberg, John D. Mccorvy et al. 10 citations

Substance abuse is on the rise, and while many people may use illicit drugs mainly due to their rewarding effects, their societal impact can range from severe, as is the case for opioids, to promising, as is the case for psychedelics. Common with all these drugs' mechanisms of action are G protein-coupled receptors (GPCRs), which lie at the center of how these drugs mediate inebriation,...

Identification of 5-HT 2A Receptor Signaling Pathways Responsible for Psychedelic Potential

bioRxiv (Cold Spring Harbor Laboratory) July 31, 2023 Jason Wallach, Andrew B. Cao, Maggie M. Calkins et al. 11 citations preprint

Summary Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT 2A receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT 2A -Gq/11 and β-arrestin2 signaling, making their respective roles unclear. To elucidate this, we developed a series of 5-HT 2A -selective ligands with varying Gq efficacies, including β-arrestin-biased...

A non-hallucinogenic LSD analog with therapeutic potential for mood disorders.

Cell Reports March 28, 2023 Vern Lewis, Emma M. Bonniwell, Janelle K. Lanham et al. 129 citations

Hallucinations limit widespread therapeutic use of psychedelics as rapidly acting antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at more than 33 aminergic G protein-coupled receptors (GPCRs). 2-Br-LSD shows partial agonism at several aminergic GPCRs, including 5-HT2A, and does not induce the head-twitch response (HTR) in...

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors

Science February 16, 2023 Maxemiliano V. Vargas, Lee E. Dunlap, Chunyang Dong et al. 467 citations

Decreased dendritic spine density in the cortex is a hallmark of several neuropsychiatric diseases, and the ability to promote cortical neuron growth has been hypothesized to underlie the rapid and sustained therapeutic effects of psychedelics. Activation of 5-hydroxytryptamine (serotonin) 2A receptors (5-HT2ARs) is essential for psychedelic-induced cortical plasticity, but it is currently...

Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs

ACS Chemical Neuroscience December 15, 2022 Michael J. Cunningham, Hailey A. Bock, Inis C. Serrano et al. 65 citations

Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. Ariadne has been tested in humans including clinical trials at Bristol-Myers Company that indicate a lack of hallucinogenic...

Bespoke library docking for 5-HT2A receptor agonists with anti-depressant activity

Nature September 28, 2022 Anat Levit Kaplan, Danielle N. Confair, Kuglae Kim et al.

There is considerable interest in screening ultralarge chemical libraries for ligand discovery, both empirically and computationally 1 – 4 . Efforts have focused on readily synthesizable molecules, inevitably leaving many chemotypes unexplored. Here we investigate structure-based docking of a bespoke virtual library of tetrahydropyridines—a scaffold that is poorly sampled by a general...

(2-Aminopropyl)benzo[β]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice.

Neuropsychopharmacology March 1, 2022 Deborah Rudin, John D. Mccorvy, Grant C. Glatfelter et al. 18 citations

Derivatives of (2-aminopropyl)indole (API) and (2-aminopropyl)benzofuran (APB) are new psychoactive substances which produce stimulant effects in vivo. (2-Aminopropyl)benzo[β]thiophene (APBT) is a novel sulfur-based analog of API and APB that has not been pharmacologically characterized. In the current study, we assessed the pharmacological effects of six APBT positional isomers in vitro, and...

DOI: 10.1038/s41386-021-01221-0 (opens in new tab) Full text (opens in new tab) Psychedelics Neuropharmacology Therapeutic applications Drug discovery